Video

Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Monica Morrow, MD, chief of Breast Service at Memorial Sloan Kettering Cancer Center, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Because there is a higher likelihood of nipple involvement in patients with larger cancers closer to the nipple, the ideal candidate for nipple sparing mastectomy would be a patients with a small peripheral breast cancer. Studies have also shown that for those patients where HER2 is over expressed, they are more likely to have nipple involvement because of a higher association to ductal carcinoma in situ (DCIS), says Morrow.

In terms of cosmetic appearance, the decision to move forward with a nipple sparing procedure versus conventional approaches depend on the placement of the nipple. For example, those with larger breasts may be poorer candidates, says Morrow, compared with patients who have smaller breasts.

<<< View more from the 2019 Lynn Sage Breast Cancer Symposium

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine